Skip to main content
. Author manuscript; available in PMC: 2008 Oct 16.
Published in final edited form as: Neurosci Lett. 2007 Aug 31;426(2):117–122. doi: 10.1016/j.neulet.2007.08.053

Figure 4. Pharmacologic inhibition on the PI3-kinase pathway with LY29002 reverses increase in [3H](R)-PK11195 binding in LPS activated macrophages.

Figure 4

(A) Bmax, reflective of the total number of binding sites, with [3H](R)-PK11195 was higher in primary human macrophages activated with LPS (black bars) compared to untreated controls (clear bars). Treatment with the PI3-kinase pathway inhibitor LY294002 (grey bars) but not MAP-kinase inhibitor U0126 (hatched bars) reversed increase in Bmax values in LPS activated macrophages (n=3, each, p<0.001).

(B) The KD (reflective of the binding affinity) was not significantly different in all the conditions (p=0.2284). Data analyzed using one-sided ANOVA.